Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Three barriers to innovative diagnostics

Although technology adoption and remuneration are significant barriers to the development and implementation of innovative diagnostics, health imperialism may be just as important.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    The Lewin Group. The Value of Diagnostics: Innovation, Adoption and Diffusion into Health Care. The Lewing Group. Washington, DC. July, 2005.

  2. 2

    Haga, B. & Burke, W. Using pharmacogenetics to improve drug safety and efficacy. JAMA 2004; 291, 2869–2871.

    CAS  Article  Google Scholar 

  3. 3

    Stoler, M. & Schiffman, M., for the Atypical Squamous Cells of Undetermined Significance–Low-grade Squamous Intraepithelial Lesion Triage Study Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285, 1500–1505.

    CAS  Article  Google Scholar 

  4. 4

    Billings P. Genetic nondiscrimination. Nature Genetics 2005; 37, 559–560.

    CAS  Article  Google Scholar 

Download references

Author information



Rights and permissions

Reprints and Permissions

About this article

Cite this article

Billings, P. Three barriers to innovative diagnostics. Nat Biotechnol 24, 917–918 (2006).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing